Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Sepsis"

8 News Found

Sir H. N. Reliance Foundation Hospital launches Sepsis Cart
Healthcare | September 14, 2023

Sir H. N. Reliance Foundation Hospital launches Sepsis Cart

The hospital hosted a two-day event with top internal and external faculty and medical experts


Sanofi completes closing for potential first-in-class vaccine against ExPEC
News | November 16, 2023

Sanofi completes closing for potential first-in-class vaccine against ExPEC

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis


Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData
News | December 07, 2022

Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData

The use of procalcitonin testing for sepsis management is highest in the US


Good microbiome and probiotics key to good health
Healthcare | April 04, 2022

Good microbiome and probiotics key to good health

The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram


New spesolimab data show promising results in patients with generalised pustular psoriasis flares
Biotech | March 28, 2022

New spesolimab data show promising results in patients with generalised pustular psoriasis flares

Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status


Amrita University launches wearable device for home monitoring of glucose and BP
Digitisation | March 02, 2022

Amrita University launches wearable device for home monitoring of glucose and BP

Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home


Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
Biotech | December 13, 2021

Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia

It is a novel oral NLRP3 inflammasome inhibitor


Boehringer Ingelheim announces EMA marketing authorisation for spesolimab
Drug Approval | October 29, 2021

Boehringer Ingelheim announces EMA marketing authorisation for spesolimab

Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules